NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today ...
NEW YORK--(BUSINESS WIRE)--Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced positive top-line results from the first of two pivotal phase 3 clinical trials evaluating the efficacy and safety ...
While each product featured is independently selected by our editors, we may include paid promotion. If you buy something through our links, we may earn commission. Read more about our Product Review ...
After conquering grocery, SYNERGY founder GT Dave tells us why he has big plans with a smaller-sized bottle for the convenience channel. A: Kombucha is a naturally sparkling, fermented tea that is ...
Synergy Pharmaceuticals Announces Plans to Initiate a Phase 2 Study of SP-333 for Opioid-Induced Con
NEW YORK--(BUSINESS WIRE)-- Synergy Pharmaceuticals Inc. (NAS: SGYP) today announced plans to move forward this quarter with SP-333, its proprietary next-generation guanylate cyclase-C (GC-C) agonist, ...
Experts expect functional beverages like Kombucha will drive sales growth in 2023 and beyond. A: As of 2023, the Kombucha market is valued at $3.4 billion with a promising revenue forecast over the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback